This smallcap pharma company has zoomed 44% in 3 days on strong Q4 results
Since February 2, 2023, the stock price of Neuland Labs more-than-doubled or zoomed 116 per cent from level of Rs 1,409.7515-05-2023
15-05-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper advertisement regarding audited financial results for the quarter and year ended March 31, 202312-05-2023
NEULAND LABORATORIES LTD. - 524558 - Machine-Readable Version / Legible Copy Of The Financial Results For The Quarter And Year Ended March 31, 2023
Machine-readable version / legible copy of the financial results for the quarter and year ended March 31, 202312-05-2023
Neuland Laboratories Results Earnings Call for Q4FY23
Conference Call with Neuland Laboratories Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.11-05-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the link of the audio recording of the Earnings call for the quarter and year ended March 31, 2023, conducted on May 11, 202311-05-2023
NEULAND LABORATORIES LTD. - 524558 - Book Closure For Dividend And Annual General Meeting Scheduled On Thursday, July 27, 2023.
39th Annual General Meeting (AGM) of the members of the Company is scheduled to be held on Thursday, July 27, 2023. The Register of Members and the Share Transfer Books of the Company shall remain closed from Wednesday, July 12, 2023, to Friday, July 14, 2023 (both days inclusive) for the purpose of the Dividend and Annual General Meeting of the Company.11-05-2023
NEULAND LABORATORIES LTD. - 524558 - Outcome Of Board Meeting
The Board of Directors of the Company at its meeting held on May 11, 2023, has inter alia approved the following: 1. Re-appointment of Mr. Davuluri Sucheth Rao (DIN: 00108880) as Whole Time Director of the Company designated as Vice Chairman & CEO, for a further period of 5 (five) years, w.e.f. August 1, 2023, basis the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting. 2. Re-appointment of Dr. Davuluri Rama Mohan Rao (DIN: 00107737) as Whole Time Director of the Company designated as Executive Chairman, for a further period of 5 (five) years, w.e.f. April 1, 2024, basis the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting.11-05-2023
NEULAND LABORATORIES LTD. - 524558 - Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2023
Disclosure Of Related Party Transactions For The Half Year Ended March 31, 202311-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Neuland Laboratories Ltd.
Pharmaceuticals company Neuland Laboratories announced Q4FY23 & FY23 results: Q4FY23: Total Income for Q4FY23 at Rs 415.1 crore (+61.8% YoY) led by growth in Specialty and CMS segment EBITDA for Q4FY23 at Rs 127.8 crore (+224.8% YoY) EBITDA Margin for Q4FY23 at 30.8% (increased by 1550 bps YoY) PAT for Q4FY23 at Rs 84.5 crore (+287.2% YoY) Net Debt stood at Rs 63.0 crore as at Q4FY23 end compared to Rs 212.0 crores as at Q4FY22 end and Rs 72.0 crores as at Q3FY23 end FY23: Total Income for FY23 at Rs 1,200.9 crore (+26.0% YoY) led by growth in Specialty and CMS segment EBITDA for FY23 at Rs 281.1 crore (+94.8% YoY) EBITDA Margin for FY23 at 23.4% (increased by 830 bps YoY) due to a better business mix PAT for FY23 at Rs 163.1 crore (+156.7% YoY) due to a slower increase in depreciation compared to an increase in EBITDA Debt/Equity stood at 0.12x due to the retirement of Rs 113.6 crore borrowings (net) in FY23 Net Debt stood at Rs 63.0 crore as at FY23 end compared to Rs 212.0 crore as at FY22 end Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We crossed several significant milestones in FY23 with business driven by ongoing growth in the high margin Specialty and CMS business. The performance of this fiscal reflects the various initiatives we have taken in line with our strategy over the last few years, playing out now. We believe that this puts us in a strong position as we look to consolidate the healthy momentum going forward.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added “We are happy to state that our focus on R&D; and project management saw us achieve our highest ever profitability margins in FY23. We executed a number of CMS projects during the year resulting in the business recording significant growth and contributing close to half the Q4 revenues. We expect this momentum to continue in the future as well on account of new customers increasingly accepting Neuland as an established CDMO.” Result PDF11-05-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investors/Analysts Presentation on the Financial Results of the Company for the quarter and year ended March 31, 2023.11-05-2023